HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance

Ítems similars

• Cost-Effectiveness of HCV Core Antigen versus PCR for Monitoring Treatment Response in DAAS-Treated Egyptian Patients
  per: Mohammed Nouh, et al.
  Publicat: (2020-06-01)
• Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
  per: Gao X, et al.
  Publicat: (2020-12-01)
• Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
  per: Reham M. Dawood, et al.
  Publicat: (2022-08-01)
• Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients
  per: Ghada M. Salum, et al.
  Publicat: (2020-09-01)
• HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
  per: Devis Pascut, et al.
  Publicat: (2020-06-01)